493 related articles for article (PubMed ID: 11036892)
1. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
3. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mignotte H; Lasset C; Bonadona V; Lesur A; Luporsi E; Rodier JF; Cutuli B; Lasry S; Mauriac L; Granon C; Kerr C; Giard S; Hill C; de Lafontan B; de Gislain C; D'Anjou J; Fondrinier E; Lefeuvre C; Parache RM; Chauvin F
Int J Cancer; 1998 May; 76(3):325-30. PubMed ID: 9579567
[TBL] [Abstract][Full Text] [Related]
4. One step forward or one step back with tamoxifen?
Gelmon K
Lancet; 2000 Sep; 356(9233):868-9. PubMed ID: 11036885
[No Abstract] [Full Text] [Related]
5. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.
Jones ME; van Leeuwen FE; Hoogendoorn WE; Mourits MJ; Hollema H; van Boven H; Press MF; Bernstein L; Swerdlow AJ
Breast Cancer Res; 2012 Jun; 14(3):R91. PubMed ID: 22691381
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
7. Should tamoxifen users be screened for endometrial lesions?
Neven P; Vergote I
Lancet; 1998 Jan; 351(9097):155-7. PubMed ID: 9449866
[No Abstract] [Full Text] [Related]
8. The effects of tamoxifen treatment on the endometrium.
Daniel Y; Inbar M; Bar-Am A; Peyser MR; Lessing JB
Fertil Steril; 1996 Jun; 65(6):1083-9. PubMed ID: 8641477
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
10. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
Hoff PM; Valero V; Buzdar AU; Singletary SE; Theriault RL; Booser D; Asmar L; Frye D; McNeese MD; Hortobagyi GN
Cancer; 2000 May; 88(9):2054-60. PubMed ID: 10813717
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas.
Ramondetta LM; Palazzo JP; Dunton CJ; Kovatich AJ; Carlson JA
Anticancer Res; 1998; 18(6B):4661-5. PubMed ID: 9891537
[TBL] [Abstract][Full Text] [Related]
12. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen therapy--long-term results and complications.
Moore MP; Kinne DW
Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
[No Abstract] [Full Text] [Related]
15. Tamoxifen therapy for breast cancer and endometrial cancer risk.
Bernstein L; Deapen D; Cerhan JR; Schwartz SM; Liff J; McGann-Maloney E; Perlman JA; Ford L
J Natl Cancer Inst; 1999 Oct; 91(19):1654-62. PubMed ID: 10511593
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
[TBL] [Abstract][Full Text] [Related]
17. The tamoxifen dilemma.
White IN
Carcinogenesis; 1999 Jul; 20(7):1153-60. PubMed ID: 10383884
[TBL] [Abstract][Full Text] [Related]
18. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536
[TBL] [Abstract][Full Text] [Related]
19. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
20. [Tamoxifen and endometrial pathology].
Negoiţă M; Terinte C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
